Trial
NCT04157335
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Nasal Polyposis
Intervention
Benralizumab 30 mg
Why stopped
The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-19